The latest announcement is out from Poseida Therapeutics (PSTX).
Poseida Therapeutics, Inc. has recently shared updates on their cutting-edge cancer research at the AACR Annual Meeting in San Diego, revealing progress in their Phase 1 studies for two innovative therapies. The company’s press release and scientific posters, showcasing their advancements, have sparked interest within the investment community, as they hint at Poseida’s potential impact on cancer treatment and their future growth in the biotech sector.
See more insights into PSTX stock on TipRanks’ Stock Analysis page.
